📚 Central Nervous System Special Senses Module L1 Neurotransmitters

📚 Lecture Overview

This summary covers the biochemical synthesis, signaling mechanisms, receptor types, and catabolism of major central and peripheral nervous system neurotransmitters. It details the operational differences between ionotropic and metabotropic receptors during synaptic transmission. Finally, it explores the clinical pathologies and pharmacological interventions associated with neurotransmitter dysregulation, including Parkinson's disease, Alzheimer's disease, schizophrenia, depression, and toxin exposures.

🎯 Key Concepts & Definitions

• Neurotransmitters: Chemical messengers that transmit signals across the synaptic cleft from a presynaptic neuron to a postsynaptic target cell (neuron, muscle, or gland cell).
• Ionotropic Receptors: Ligand-gated ion channels that open directly upon neurotransmitter binding, enabling rapid ion movement across the postsynaptic membrane.
• Metabotropic Receptors: G-protein coupled receptors (GPCRs) that initiate intracellular signaling cascades upon neurotransmitter binding.
• Excitatory Neurotransmitters: Transmitters that cause postsynaptic membrane depolarization, triggering an action potential.
• Inhibitory Neurotransmitters: Transmitters that cause postsynaptic membrane hyperpolarization, inhibiting action potential generation.
• Excitotoxicity: Neuronal damage or death resulting from excessive stimulation by excitatory neurotransmitters, primarily mediated by N-methyl-D-aspartate receptors (NMDAR).

📖 Main Content

1. Synaptic Transmission & Receptor Types

A chemical synapse consists of three structural components: the presynaptic membrane, the postsynaptic membrane, and the synaptic cleft.

Ionotropic Receptors (Ligand-Gated Ion Channels)

• Direct ion channel opening upon ligand binding.
• Cation Flux ($Na^+$, $Ca^{2+}$): Causes depolarization of the postsynaptic membrane, triggering an action potential (stimulatory/excitatory).
• Anion Flux ($Cl^-$): Causes hyperpolarization of the postsynaptic membrane, making action potential generation harder (inhibitory).

Metabotropic Receptors (G-Protein Coupled Receptors)

• Act via second messenger systems to alter cellular functions indirectly.

2. Acetylcholine (ACh)

Synthesis & Degradation

• Synthesis: Synthesized in cholinergic nerve endings from choline and acetyl-CoA by the enzyme choline acetyltransferase.
• Degradation: Rapidly broken down in the synaptic cleft by acetylcholinesterase. The remainder is taken back up into the nerve cell by transporters.

Physiological Actions

• Active in both central and peripheral nervous systems.
• Excitatory in all locations except the heart (where it exerts inhibitory actions).

Receptor Subtypes

• Nicotinic Receptors: Ionotropic; bind nicotine; located at autonomic ganglia and neuromuscular junctions (NMJ).
• Muscarinic Receptors: Metabotropic; widespread in the brain, heart, smooth muscle, glands, and peripheral arteries; specifically inhibited by atropine.

Clinical Applications

• Glaucoma & Post-Op Recovery: ACh agonists and acetylcholinesterase inhibitors increase eye muscle accommodation tone and stimulate intestinal function post-surgery.
• Organophosphate Insecticides: Inhibit acetylcholinesterase, causing excess ACh accumulation. Symptoms include diarrhea, excessive lacrimation/salivation, bronchoconstriction, and bradycardia. Treated with atropine.
• Myasthenia Gravis (MG): Autoimmune disorder with antibodies against nicotinic ACh receptors at the NMJ. Severe cases cause respiratory failure. Treated with acetylcholinesterase inhibitors.
• Botulism: Toxin prevents the release of ACh, causing effector muscle paralysis.
• Alzheimer's Disease: Associated with ACh deficiency in specific brain regions. Treated with acetylcholinesterase inhibitors.

3. Catecholamines (Norepinephrine, Epinephrine, Dopamine)

Synthesis & Catabolism

• Synthesis: Produced from the amino acid tyrosine (derived from phenylalanine hydroxylation in the liver).
• Catabolism: Involves two sequential enzymatic steps:
  1. Methylation by Catechol O-methyltransferase (COMT) using S-adenosyl methionine (SAM) as a methyl donor.
  2. Deamination by Monoamine oxidase (MAO).
• Major Metabolites:
• Epinephrine & Norepinephrine → Vanillylmandelic acid (VMA) (elevated in pheochromocytoma).
• Dopamine → Homovanillic acid (HVA).

Functions

• Norepinephrine & Epinephrine: Produced in the adrenal medulla, CNS, and sympathetic PNS. Bind $\alpha$- and $\beta$-adrenergic receptors (GPCRs). Excitatory transmitters governing the fight-or-flight response; norepinephrine increases arousal and alertness.
• Dopamine: Acts via metabotropic dopaminergic receptors. Regulates CNS reward, mood, attention, memory, and feeding. Coordinates motor control in the extrapyramidal system by inhibiting unnecessary movements.

Clinical Applications

• Parkinson's Disease: Destruction of the substantia nigra leads to dopamine depletion, producing uncontrollable muscle tremors. Treated by administering L-dopa.
• Schizophrenia:
• High dopamine in the limbic system → Positive symptoms (delusions, hallucinations, thought disorders).
• Low dopamine in the prefrontal cortex → Negative symptoms (social withdrawal, flat affect, cognitive decline).

4. Serotonin (5-HT)

Synthesis, Receptors, & Catabolism

• Synthesis: Derived from the amino acid tryptophan in two enzymatic steps.
• Receptors: Seven classes ($5-HT_1$ to $5-HT_7$). All are metabotropic EXCEPT $5-HT_3$, which is ionotropic.
• Catabolism: Oxidative deamination by MAO yields 5-hydroxyindole acetic acid (5-HIAA). Urinary 5-HIAA increases in malignant carcinoid syndrome.

Functions

• Gastrointestinal: Most abundant in gut enterochromaffin cells; controls peristalsis, digestion, absorption, and hormone release.
• CNS: Concentrated in upper brainstem neurons projecting to the cortex and spinal cord; regulates sleep, mood, appetite, satiety, sensory perception, pain control, fear, and sexual behavior.

Clinical Applications

• Deficiency: Causes depression, mood swings, insomnia, OCD, aggression, and carbohydrate cravings.
• $5-HT_3$ Blocker (Ondansetron): Antiemetic used during chemotherapy.
• $5-HT_{1D}$ Agonist (Sumatriptan): Used to treat migraines.
• Amine Theory of Depression: Proposes depression stems from deficient synaptic amines (norepinephrine/serotonin). Treated with MAO inhibitors, Tricyclic Antidepressants (TCAs), and SSRIs.

5. Histamine

Synthesis & Distribution

• Synthesis: Formed by decarboxylation of histidine.
• Release Sites:
  1. Mast Cells: Released upon allergen binding to IgE; acts on $H_1$ receptors mediating allergy and inflammation.
  2. Enterochromaffin-like Cells: Stimulates stomach parietal cells to secrete acid via $H_2$ receptors.
  3. Hypothalamus: Regulates arousal and the sleep-wake cycle.
• Receptors: Four types ($H_1$–$H_4$), all metabotropic.

Clinical Applications

• $H_1$ Inhibitors: Antiallergy medications; cross the blood-brain barrier causing sedation.
• $H_2$ Inhibitors: Drugs like cimetidine and ranitidine block gastric acid production to treat peptic ulcers.

6. Amino Acid Neurotransmitters

Gamma-Aminobutyric Acid (GABA)

• Synthesis: Derived from decarboxylation of glutamate by glutamate decarboxylase (GAD) requiring Pyridoxal Phosphate (PLP / Vitamin B6).
• Function: Primary inhibitory neurotransmitter in the CNS; acts as a brake on excitability, refining motor control and regulating anxiety.
• Receptors:
• GABA-A: Ionotropic.
• GABA-B: Metabotropic.
• Clinical Applications:
• Underproduction (due to GAD or Vitamin B6 deficiency) triggers anxiety or seizures.
• Benzodiazepines: Bind GABA receptors to potentiate endogenous GABA action (anxiolytic and muscle relaxant).
• Barbiturates: Bind and directly activate GABA receptors without needing endogenous GABA (high risk of fatal overdose).
• Tetanus: Tetanospasmin toxin prevents GABA release, causing violent spastic paralysis.

Glutamate

• Function: Primary excitatory neurotransmitter in the CNS; regulates general excitability, memory, learning, and cognition.
• Receptors: Metabotropic glutamate receptors (mGluRs) and ionotropic receptors like the N-methyl-D-aspartate receptor (NMDAR).
• Clinical Applications:
• Excess glutamate activity leads to epilepsy.
• Excitotoxicity: Overactivation of NMDAR following a stroke damages postsynaptic neurons.

📊 Visual Learning

Diagram 1: Postsynaptic Receptor Mechanisms

Diagram 2: Chemical Classification of Neurotransmitters

Diagram 3: Synaptic Transmission Sequence

💡 Important Points to Remember

• Acetylcholine is excitatory everywhere except in the heart, where it acts as an inhibitor.
• Nicotinic receptors are ionotropic; Muscarinic receptors are metabotropic and selectively blocked by atropine.
• Precursors to memorize:
• Tyrosine → Catecholamines (Dopamine, Norepinephrine, Epinephrine)
• Tryptophan → Serotonin (5-HT)
• Histidine → Histamine
• Glutamate → GABA (via GAD + PLP/Vitamin B6)
• VMA is the main metabolite of epinephrine/norepinephrine (elevated in pheochromocytoma); HVA is the main metabolite of dopamine.
• 5-HIAA is the urinary metabolite of serotonin (elevated in malignant carcinoid syndrome).
• 5-HT3 is the ONLY ionotropic serotonin receptor; all other serotonin receptors ($5-HT_1$–$5-HT_7$) are metabotropic.
• Barbiturates directly activate GABA receptors independently of GABA (high overdose risk), whereas Benzodiazepines only potentiate endogenous GABA.
• Botulinum toxin prevents ACh release (→ flaccid paralysis), whereas Tetanospasmin toxin prevents GABA release (→ spastic paralysis).
• Organophosphate poisoning causes excess ACh due to acetylcholinesterase inhibition and is antagonized by atropine.

⚠️ Common Exam Questions & Traps

Exam Traps & Tricks

1. Receptor Type Swaps:
   * Trap: Examiners often ask which serotonin receptor is ionotropic.
   * Fact: Only $5-HT_3$ is ionotropic; $5-HT_1$ through $5-HT_7$ (except 3) are metabotropic.
   * Trap: Confusing GABA receptor types. GABA-A is ionotropic, GABA-B is metabotropic.

2. Mechanism Differences: Benzodiazepines vs. Barbiturates:
   * Trap: Suggesting benzodiazepines can open channels without GABA present.
   * Fact: Benzodiazepines potentiate endogenous GABA. Barbiturates directly activate the receptor even in the absence of GABA, making them far more toxic in overdose.

3. Flaccid vs. Spastic Paralysis Toxin Mechanisms:
   * Trap: Reversing the neurotransmitter targets of Botulism and Tetanus.
   * Fact: Botulism stops ACh release → Flaccid Paralysis. Tetanus stops GABA release → Spastic Paralysis.

4. Metabolite Matching:
   * Trap: Matching VMA with carcinoid syndrome or 5-HIAA with pheochromocytoma.
   * Fact: VMA = Pheochromocytoma (Catecholamines). 5-HIAA = Malignant Carcinoid Syndrome (Serotonin). HVA = Dopamine catabolism.

5. Anatomical Dopamine Traps in Schizophrenia:
   * Trap: Equating high dopamine with negative symptoms.
   * Fact: High dopamine in the limbic system causes positive symptoms. Low dopamine in the prefrontal cortex causes negative symptoms.

📝 Quick Review Checklist

I can differentiate between ionotropic (cation/anion flux) and metabotropic GPCR pathways.
I know the rate-limiting precursors and degradation metabolites for ACh, Dopamine, NE, Epinephrine, Serotonin, Histamine, GABA, and Glutamate.
I can state the specific receptor targets for atropine, ondansetron, sumatriptan, cimetidine, and ranitidine.
I can explain the mechanism differences between Benzodiazepines and Barbiturates on GABA receptors.
I understand why Botulism causes flaccid paralysis while Tetanus causes spastic paralysis.
I can identify the diagnostic urinary metabolites for pheochromocytoma (VMA) and carcinoid syndrome (5-HIAA).
I understand the pathology of Parkinson's disease, Alzheimer's disease, Myasthenia Gravis, and Schizophrenia as presented in the lecture.